Guidelines

Facility Readiness Goal Date Decisions Under GDUFA

Facility Readiness Goal Date Decisions Under GDUFA

FDA

The Generic Drug User Fee Amendments (GDUFA) aim to streamline the approval process for generic drugs, ensuring timely access to affordable medications. A crucial aspect of this process is the Facility Readiness Goal Date Decisions, which influence the FDAโ€™s timelines for reviewing and approving generic drug applications. Key Highlights from ... Read More
Explanation of FDA Designations

Explanation of FDA Designations

FDA

Navigating the complex landscape of clinical trials can be overwhelming, especially when it comes to understanding the various designations put forth by the U.S. Food and Drug Administration (FDA). Here’s a breakdown of some crucial designations: Standard Designation: Standard designation is the typical pathway for drug development, involving preclinical studies ... Read More
EU and US GMPs | Understanding the Similarities and Differences

EU and US GMPs | Understanding the Similarities and Differences

EMA, FDA

Similarities 1) cover a wide range of products, including RX drugs, OTCs, biologics, & medical devices. Regulations apply to all stages of manufacturing, from raw material sourcing to the final packaging and distribution. 2) require manufacturers to provide adequate training to their employees. 3) prescribe certain standards for facility design ... Read More
Common Terms Used in USFDA Inspections

Common Terms Used in USFDA Inspections

FDA

Types of USFDA Inspections The agency also conducts inspections to verify the reliability, integrity and compliance of r&d facilities, testing labs, cmo, clinical and non-clinical research being reviewed in support of pending applications. FDA Forms 482, 483 and 484 Establishment Inspection Report (EIR) A comprehensive report that provides a detailed ... Read More
Patents and Exclusivities | Differences and Importance

Patents and Exclusivities | Differences and Importance

FDA

Patents Property right issued by USPTO to an inventor โ€œto exclude others from making, using, sale, import the invention into the US for a period of 20 years from the date of filing”. Patents can be issued or expire at any time regardless of the drugโ€™s approval status Patent information ... Read More
Guidelines on Good Distribution Practice of Medicinal Products

Guidelines on Good Distribution Practice of Medicinal Products

Quality Management The organisationโ€™s management is responsible for the quality system, which requires their leadership and active participation supported by staff commitment. The Responsible Person is to ensure that a Quality Management System is implemented and maintained. The Management is to ensure that all parts of the quality system are ... Read More
Qualification and Re-Qualification of Personnel Involved in Laboratory Activities

Qualification and Re-Qualification of Personnel Involved in Laboratory Activities

ISO

Qualification and re-qualification of all personnel involved in laboratory activities are critical aspects, which contribute to ensuring the validity of results. This article describes how to manage the qualification of new personnel in the different phases as well ensuring maintenance of competences and the steps to be undertaken to re-qualify ... Read More
Data Quality Framework (DQF) for EU Medicines Regulation

Data Quality Framework (DQF) for EU Medicines Regulation

EMA

Data Quality (DQ) In general terms, quality is defined as an attribute of a product or service that defines the degree to which it meets customer and other stakeholder needs within statutory and regulatory requirements or its fitness for intended use. Where Data quality is defined as: โ€œfitness for purpose ... Read More
Difference Between CBER and CDER

Difference Between CBER and CDER

FDA

๐—–๐—•๐—˜๐—ฅ (๐—–๐—ฒ๐—ป๐˜๐—ฒ๐—ฟ ๐—ณ๐—ผ๐—ฟ ๐—•๐—ถ๐—ผ๐—น๐—ผ๐—ด๐—ถ๐—ฐ๐˜€ ๐—˜๐˜ƒ๐—ฎ๐—น๐˜‚๐—ฎ๐˜๐—ถ๐—ผ๐—ป ๐—ฎ๐—ป๐—ฑ ๐—ฅ๐—ฒ๐˜€๐—ฒ๐—ฎ๐—ฟ๐—ฐ๐—ต) ๐—ฅ๐—ฒ๐—ด๐˜‚๐—น๐—ฎ๐˜๐—ผ๐—ฟ๐˜† ๐—”๐˜‚๐˜๐—ต๐—ผ๐—ฟ๐—ถ๐˜๐˜†: CBER regulates biological products, which are complex substances derived from living organisms or their byproducts. These products include vaccines, blood products, gene therapies, tissues, and medical devices that contain biological components. ๐—ฅ๐—ฒ๐˜ƒ๐—ถ๐—ฒ๐˜„ ๐—ฃ๐—ฟ๐—ผ๐—ฐ๐—ฒ๐˜€๐˜€: CBER reviews applications for Biologics License Applications (BLAs) ... Read More
Estimated Time Frames for Obtaining FDA Authorization

Estimated Time Frames for Obtaining FDA Authorization

๐—•๐—ถ๐—ผ๐—น๐—ผ๐—ด๐—ถ๐—ฐ๐˜€ The approval timeline for a biologic can vary depending on the complexity of the product and the data required to support its safety and effectiveness. ๐—ฃ๐—ฟ๐—ฒ-๐—œ๐—ก๐—— ๐—ฑ๐—ฒ๐˜ƒ๐—ฒ๐—น๐—ผ๐—ฝ๐—บ๐—ฒ๐—ป๐˜: 1-2 years๐—œ๐—ก๐——: 1-2 years๐—–๐—น๐—ถ๐—ป๐—ถ๐—ฐ๐—ฎ๐—น ๐˜๐—ฟ๐—ถ๐—ฎ๐—น๐˜€: 3-7 years๐—•๐—Ÿ๐—” ๐˜€๐˜‚๐—ฏ๐—บ๐—ถ๐˜€๐˜€๐—ถ๐—ผ๐—ป: 6 months๐—™๐——๐—” ๐—ฟ๐—ฒ๐˜ƒ๐—ถ๐—ฒ๐˜„: 6-12 months๐—ง๐—ผ๐˜๐—ฎ๐—น ๐—ฎ๐—ฝ๐—ฝ๐—ฟ๐—ผ๐˜ƒ๐—ฎ๐—น ๐˜๐—ถ๐—บ๐—ฒ: 5-10 years ๐—•๐—ถ๐—ผ๐˜€๐—ถ๐—บ๐—ถ๐—น๐—ฎ๐—ฟ๐˜€ The approval timeline for ... Read More